leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   93 Trials   93 Trials   2194 News 


«12...1718192021222324252627...3334»
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, Monotherapy:  High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) -  May 27, 2020   
    P1/2,  N=163, Recruiting, 
    Trial completion date: Jan 2025 --> Dec 2026 | Trial primary completion date: Feb 2020 --> Dec 2021
  • ||||||||||  Erleada (apalutamide) / J&J
    Trial completion date, Trial primary completion date:  Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer (clinicaltrials.gov) -  May 6, 2020   
    P2,  N=57, Recruiting, 
    Completed --> Active, not recruiting | Trial completion date: Nov 2019 --> May 2021 Trial completion date: Apr 2020 --> Oct 2020 | Trial primary completion date: Apr 2020 --> Oct 2020
  • ||||||||||  progesterone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
    Trial completion date, Trial primary completion date:  Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea (clinicaltrials.gov) -  Apr 14, 2020   
    P=N/A,  N=80, Active, not recruiting, 
    Recruiting --> Suspended Trial completion date: Jan 2019 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2021
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas
    Trial completion date:  Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer (clinicaltrials.gov) -  Apr 8, 2020   
    P2,  N=11, Active, not recruiting, 
    Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Jun 2022 --> Jun 2020
  • ||||||||||  Erleada (apalutamide) / J&J
    Trial termination:  A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer (clinicaltrials.gov) -  Mar 30, 2020   
    P2,  N=9, Terminated, 
    Recruiting --> Active, not recruiting | N=900 --> 554 | Trial completion date: Oct 2021 --> Apr 2021 | Trial primary completion date: Oct 2021 --> Apr 2021 Active, not recruiting --> Terminated; Safety concerns
  • ||||||||||  Livial (tibolone) / Organon, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Psychological Impact of Amenorrhea in Women With Endometriosis (clinicaltrials.gov) -  Mar 24, 2020   
    P4,  N=50, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: May 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Sep 2020
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas
    Trial completion date, Trial primary completion date:  Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer (clinicaltrials.gov) -  Mar 16, 2020   
    P2,  N=9, Active, not recruiting, 
    Trial completion date: May 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Sep 2020 Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
  • ||||||||||  Lupron Depot (leuprorelin depot) / AbbVie, Takeda
    Recurrent Pneumothorax in a Young Female (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area H) -  Mar 15, 2020 - Abstract #ATS2020ATS_9263;    
    She has tolerated therapy with no recurrence of pneumothorax.This case showcases the difficulty of diagnosis even though there was clinical suspicion and highlights the need for aggressive hormonal suppression to effectively treat this condition. Many patients do not have classic presentation and there is no definitive lab or tissue confirmation, so often this is a diagnosis of exclusion.
  • ||||||||||  Lupron Depot (leuprorelin depot) / AbbVie, Takeda, minocycline / Generic mfg., Cubicin (daptomycin) / Merck (MSD)
    A Case of Drug-Induced Acute Eosinophilic Pneumonia (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area G) -  Mar 15, 2020 - Abstract #ATS2020ATS_7868;    
    To the best of our knowledge, there have only been 37 cases that had diagnostic procedures which confirmed daptomycin as a cause of AEP. Although this is a rare disease, if it is promptly identified and treated, the outcome is excellent with low recurrence rate.
  • ||||||||||  tranexamic acid / Generic mfg., Lupron Depot (leuprorelin depot) / AbbVie, Takeda, bicalutamide / Generic mfg.
    Critical Anemia and Disseminated Intravascular Coagulation with Excessive Fibrinolysis in Prostate Cancer (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area G) -  Mar 15, 2020 - Abstract #ATS2020ATS_5437;    
    Administration of antifibrinolytic agent TXA while controversial is used to directly treat the excessive fibrinolysis. This strategy should be considered in patients requiring critical care treatment for life threatening fibrinolytic disease.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Trial completion:  The Effects of Reproductive Hormones on Mood and Behavior (clinicaltrials.gov) -  Mar 5, 2020   
    P=N/A,  N=124, Completed, 
    This strategy should be considered in patients requiring critical care treatment for life threatening fibrinolytic disease. Recruiting --> Completed